Loading
High blood sugar as a side effect of drugs that block the PI3K/AKT pathway, because the same pathway carries insulin's signal in muscle and liver. It is the main reason these otherwise effective breast cancer drugs are hard to give.
Alpelisib causes hyperglycaemia in about 65% of patients (grade 3-4 in a third), capivasertib and everolimus less often; steroids and some immunotherapy-induced diabetes also raise glucose. Management is screening for pre-diabetes, metformin (often prophylactic), SGLT2 inhibitors, dietary carbohydrate restriction and dose modification; mutant-selective PI3Kα inhibitors (inavolisib, RLY-2608) were designed to reduce it. Hyperglycaemia is a textbook on-target toxicity: the pathway that drives PIK3CA-mutant cancers is the same one insulin uses, and the ketogenic-diet-plus-PI3K-inhibitor hypothesis arose directly from this observation.
Showing the molecule this term concerns: Alpelisib.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Inavolisib, Alpelisib, Capivasertib.
Shares AKT1 E17K mutation, PIK3CA mutation, Capivasertib.
Shares Alpelisib, Capivasertib, Everolimus.
Shares Inavolisib, Alpelisib, Capivasertib, Everolimus.
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation.
Shares Inavolisib, Alpelisib.
Shares Alpelisib, Capivasertib, Everolimus.
Shares Therapeutic index (therapeutic window), Dose reduction, interruption and discontinuation.